Gillett Daniel, Senanayake Russell, MacFarlane James, van der Meulen Merel, Koulouri Olympia, Powlson Andrew S, Crawford Rosy, Gillett Bethany, Bird Nick, Heard Sarah, Kolias Angelos, Mannion Richard, Aloj Luigi, Mendichovszky Iosif A, Cheow Heok, Bashari Waiel A, Gurnell Mark
Department of Nuclear Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ, UK.
Cambridge Endocrine Molecular Imaging Group, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ, UK.
EJNMMI Res. 2022 May 7;12(1):26. doi: 10.1186/s13550-022-00899-7.
Pituitary adenomas (PA) affect ~ 1:1200 of the population and can cause a wide range of symptoms due to hormone over-secretion, loss of normal pituitary gland function and/or compression of visual pathways, resulting in significantly impaired quality of life. Surgery is potentially curative if the location of the adenoma can be determined. However, standard structural (anatomical) imaging, in the form of MRI, is unable to locate all tumors, especially microadenomas (< 1 cm diameter). In such cases, functional imaging [C-methionine PET/CT (Met-PET)] can facilitate tumor detection, although may be inconclusive when the adenoma is less metabolically active. We, therefore, explored whether subtraction imaging, comparing findings between two Met-PET scans with medical therapy-induced suppression of tumor activity in the intervening period, could increase confidence in adenoma localization. In addition, we assessed whether normalization to a reference region improved consistency of pituitary gland signal in healthy volunteers who underwent two Met-PET scans without medical suppression.
We found that the mean percentage differences in maximum pituitary uptake between two Met-PET scans in healthy volunteers were 2.4% for (SUVr) [cerebellum], 8.8% for SUVr [pons], 5.2% for SUVr [gray matter] and 23.1% for the SUVbw [no region]. Laterality, as measured by contrast-noise ratio (CNR), indicated the correct location of the adenoma in all three image types with mean CNR values of 6.2, 8.1 and 11.1 for SUVbw, SUVbwSub and SUVrSub [cerebellum], respectively. Subtraction imaging improved CNR in 60% and 100% of patients when using images generated from SUVbw [no region] and SUVr [cerebellum] scans compared to standard clinical SUVbw imaging.
Met-PET scans should be normalized to the cerebellum to minimize the effects of physiological variation in pituitary gland uptake of 11C-methionine, especially when comparing serial imaging. Subtraction imaging following endocrine suppression of tumor function improved lateralization of PA when compared with single time point clinical Met-PET but, importantly, only if the images were normalized to the cerebellum prior to subtraction.
垂体腺瘤(PA)影响约1/1200的人群,由于激素分泌过多、垂体正常功能丧失和/或视觉通路受压,可导致多种症状,从而显著损害生活质量。如果能确定腺瘤的位置,手术有可能治愈。然而,标准的结构(解剖)成像,即MRI,无法定位所有肿瘤,尤其是微腺瘤(直径<1cm)。在这种情况下,功能成像[¹¹C-蛋氨酸PET/CT(Met-PET)]有助于肿瘤检测,尽管当腺瘤代谢活性较低时可能无法得出明确结论。因此,我们探讨了减影成像,即在两个Met-PET扫描结果之间进行比较,并结合在此期间药物治疗引起的肿瘤活性抑制,是否能提高腺瘤定位的可信度。此外,我们评估了对健康志愿者进行两次未用药物抑制的Met-PET扫描时,将垂体信号归一化到参考区域是否能提高垂体信号的一致性。
我们发现,健康志愿者两次Met-PET扫描之间垂体最大摄取量的平均百分比差异,以(SUVr)[小脑]计为2.4%,以SUVr[脑桥]计为8.8%,以SUVr[灰质]计为5.2%,以SUVbw[无区域]计为23.1%。通过对比噪声比(CNR)测量的侧别性表明,在所有三种图像类型中腺瘤的位置正确,SUVbw、SUVbwSub和SUVrSub[小脑]的平均CNR值分别为6.2、8.1和11.1。与标准临床SUVbw成像相比,当使用由SUVbw[无区域]和SUVr[小脑]扫描生成的图像时,减影成像在60%和100%的患者中提高了CNR。
Met-PET扫描应归一化到小脑,以尽量减少¹¹C-蛋氨酸垂体摄取生理变化的影响,尤其是在比较系列成像时。与单次临床Met-PET相比,肿瘤功能内分泌抑制后的减影成像改善了PA的侧别性,但重要的是,只有在减影前将图像归一化到小脑时才会如此。